RCS - Cambridge Cognition - Monument Therapeutics Partnership with FNIH

Cambridge Cognition HoldingsAnnouncement

Tue 10:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250819:nRSS9084Va&default-theme=true

RNS Number : 9084V  Cambridge Cognition Holdings PLC  19 August 2025

August 19, 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Cambridge Cognition Investment, Monument Therapeutics, Announces Partnership
with Foundation for the National Institutes of Health for Clinical Trial of
MT1988, a Novel Treatment for Schizophrenia

 

Cambridge UK, August 19, 2025 - Cambridge Cognition (AIM: COG), the brain
health software group specialising in digital health products that advance
brain health research and treatment, is pleased to report that Monument
Therapeutics, in which the Group has a 20% holding, has today announced a
partnership with the Foundation for the National Institutes of Health (FNIH)
to evaluate MT1988, a novel treatment in development for cognitive impairment
associated with schizophrenia, in a proof of principle clinical trial.

 

Schizophrenia is a serious mental health condition that ranks among the top 15
causes of disability worldwide. Its symptoms include hallucinations,
delusions, and cognitive impairments, with many individuals showing early
signs during a 'clinical high risk' (CHR) phase, which currently lacks
effective treatment options, despite its profound impact on functioning and
quality of life.

 

The trial will be conducted as part of the FNIH-managed Accelerating Medicines
Partnership® Schizophrenia (AMP® SCZ) program
(https://fnih.org/our-programs/accelerating-medicines-partnership-amp/amp-schizophrenia/)
, a public-private collaboration involving the National Institutes of Health
(NIH), major pharmaceutical companies, and nonprofit organisations with $44
million of investment committed to date. The initiative aims to accelerate the
development of more effective treatments for schizophrenia and related mental
health conditions.

 

Cambridge Cognition's proprietary digital cognitive assessment technologies
supported the early development of MT1988 and were instrumental in
establishing the foundational biomarker strategy for Monument. The Company
retains a 20% equity stake, valued at £1.8m, and future royalty rights in
Monument Therapeutics, following its spin-out in 2021.

 

Rob Baker, Joint Managing Director and Chief Operating Officer, commented:

"Monument's continued progress into patient trials is a significant step in
developing precision treatments for brain health. It highlights the value of
Cambridge Cognition's digital assessment technology in this field and
reinforces our confidence in Monument's strategy, which targets areas of high
unmet clinical need and offers strong potential for long-term value through
our equity and royalty interests."

 Enquiries

 Cambridge Cognition Holdings plc                                 Tel: 012 2381 0700

 Rob Baker, Joint Managing Director and Chief Operating Officer   press@camcog.com (mailto:press@camcog.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)                 Tel: 020 7886 2968

 Will Goode / Freddy Crossley / Mark Rogers                       (Corporate Finance)

 Rupert Dearden                                                   (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                           Tel: 020 3903 7715

 David Poutney / Amber Higgs

 Hudson Sandler (Financial PR and IR)                             Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus / Jackson Redley                  cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital
health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a
strong global brand with scalable technology that will support the rising
world demand for diagnosing and treating brain health. The Company creates
shareholder value through organic sales growth, strategic partnerships, joint
ventures, and spinouts.  The Company has identified four market sectors:

·     Clinical Studies for new pharmaceuticals;

·     Academic Research for scientists to understand CNS disorders;

·     Healthcare to provide physicians with cognitive assessments to allow
them to diagnose and treat patients; and,

·     Consumer Health & Wellness to provide individuals access to
accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

About Monument Therapeutics:

 

Monument Therapeutics is a neuroscience-focused drug development company
headquartered in Manchester, UK. It applies a unique novel drug development
strategy, leveraging digital assessments of cognition to select patients
suitable for treatment with new innovative drugs.

 

For more information, please visit www.monumenttx.com
(http://www.monumenttx.com/) .

 

About the Foundation for the National Institutes of Health:

The Foundation for the National Institutes of Health (FNIH) builds
public-private partnerships that connect leading biomedical scientists at the
National Institutes of Health (NIH) with their counterparts in life sciences
companies, academia, patient organizations, foundations, and regulatory
agencies (including the U.S. Food and Drug Administration and European
Medicines Agency). Through team science, the FNIH solves complex health
challenges and accelerates breakthroughs for patients, regardless of who they
are or what health threats they face. The FNIH contributes to the development
of new therapies, diagnostics, and potential cures; advances global health;
and helps train the next generations of scientists. Established by Congress in
1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3)
charitable organization. For more information about the FNIH, please
visit fnih.org (https://fnih.org/) .

 

 

About the Accelerating Medicines Partnership®:

 

Launched in 2014 and managed by the FNIH, the Accelerating Medicines
Partnership (AMP) program brings together the National Institutes of Health,
U.S. Food and Drug Administration, biomedical and life sciences companies,
nonprofits, patient-focused groups, and other organizations to transform the
current model for developing new diagnostics and treatments. Using
cutting-edge scientific approaches and broad sharing of research data, all
AMPs seek to improve understanding of disease pathways, facilitate better
selection of targets for drug development, and streamline processes for
bringing new treatments to patients. To learn more about AMP, visit
fnih.org/AMP (https://fnih.org/AMP) .

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASFMSUUEISESA